ArticleCureus2025
Euglycemic Diabetic Ketoacidosis (DKA) With Sodium-Glucose Transport Protein 2 (SGLT-2) Inhibitors.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SGLT2 Inhibitors: From Structure-Effect Relationship to Pharmacological Response.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case highlights a rare yet severe presentation of euglycemic diabetic ketoacidosis (DKA) in a male in his mid-eighties with type 2 diabetes mellitus managed on SGLT-2 inhibitors. Despite nearly normal blood glucose levels, he developed profound metabolic acidosis and elevated ketones, necessitating emergency intervention. Initial treatment with intravenous fluids and insulin led to temporary stabilization. Still, progressive metabolic derangement and multi-organ dysfunction resulted in a transition to palliative care, ultimately leading to his demise. This case underscores the need for heightened clinical awareness, early diagnosis, and cautious use of SGLT-2 inhibitors, particularly in elderly patients with multiple comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.